Where Will Gartner Stock Be in 5 Years?
If you’ve ever wondered what it’s like to invest in…
Buy
55
TNDM Quote, Financials, Valuation and Earnings
Last price:
$20.70
Seasonality move
:
15.46%
Day range:
$20.22 - $20.77
52-week range:
$15.75 - $53.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.39x
P/B ratio:
8.89x
Volume:
945.5K
Avg. volume:
1.6M
1-year change:
-58.29%
Market cap:
$1.4B
Revenue:
$940.2M
EPS (TTM):
-$2.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
$220.2M | -$0.61 | 7.28% | -14.02% | $35.25 |
|
ABT
Abbott Laboratories
|
$10.4B | $1.07 | 6.07% | 68.64% | $140.57 |
|
ATEC
Alphatec Holdings
|
$168.2M | -$0.12 | 22.9% | -86.45% | $18.32 |
|
BSX
Boston Scientific
|
$4.6B | $0.67 | 18.78% | 229.2% | $116.96 |
|
ISRG
Intuitive Surgical
|
$2.2B | $1.73 | 16.8% | 32.43% | $575.78 |
|
PODD
Insulet
|
$543.3M | $0.79 | 25.32% | -63.95% | $328.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
$20.72 | $35.25 | $1.4B | -- | $0.00 | 0% | 1.39x |
|
ABT
Abbott Laboratories
|
$131.30 | $140.57 | $228.4B | 17.03x | $0.59 | 1.74% | 5.42x |
|
ATEC
Alphatec Holdings
|
$12.45 | $18.32 | $1.8B | -- | $0.00 | 0% | 2.80x |
|
BSX
Boston Scientific
|
$104.50 | $116.96 | $154.6B | 76.28x | $0.00 | 0% | 8.86x |
|
ISRG
Intuitive Surgical
|
$539.54 | $575.78 | $193.4B | 79.11x | $0.00 | 0% | 22.47x |
|
PODD
Insulet
|
$321.36 | $328.73 | $22.6B | 57.80x | $0.00 | 0% | 10.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
69.23% | 2.573 | 27.4% | 1.72x |
|
ABT
Abbott Laboratories
|
21.34% | 0.621 | 6.18% | 1.27x |
|
ATEC
Alphatec Holdings
|
118.58% | 1.134 | 36.81% | 1.54x |
|
BSX
Boston Scientific
|
33.49% | 1.029 | 7.48% | 0.68x |
|
ISRG
Intuitive Surgical
|
-- | 1.838 | -- | 3.81x |
|
PODD
Insulet
|
56.03% | 1.663 | 9.18% | 3.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
$118.4M | -$120.9M | -31.97% | -81.14% | -51.5% | -$64.7M |
|
ABT
Abbott Laboratories
|
$5.9B | $1.7B | 23.5% | 31.31% | 18.43% | $933M |
|
ATEC
Alphatec Holdings
|
$116M | -$31.7M | -31.36% | -691.37% | -26.09% | -$16.7M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
|
ISRG
Intuitive Surgical
|
$1.5B | $578.1M | 15.82% | 15.82% | 25.66% | $465M |
|
PODD
Insulet
|
$409M | $88.8M | 15.79% | 36.9% | 10.07% | $48.1M |
Tandem Diabetes Care vs. Competitors
-
Which has Higher Returns TNDM or ABT?
Abbott Laboratories has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 12.79%. Tandem Diabetes Care's return on equity of -81.14% beat Abbott Laboratories's return on equity of 31.31%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M ABTAbbott Laboratories56.86% $0.76 $62.3B -
What do Analysts Say About TNDM or ABT?
Tandem Diabetes Care has a consensus price target of $35.25, signalling upside risk potential of 70.13%. On the other hand Abbott Laboratories has an analysts' consensus of $140.57 which suggests that it could grow by 7.06%. Given that Tandem Diabetes Care has higher upside potential than Abbott Laboratories, analysts believe Tandem Diabetes Care is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care7 10 0 ABTAbbott Laboratories12 9 0 -
Is TNDM or ABT More Risky?
Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.742, suggesting its less volatile than the S&P 500 by 25.819%.
-
Which is a Better Dividend Stock TNDM or ABT?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.74% to investors and pays a quarterly dividend of $0.59 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TNDM or ABT?
Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Tandem Diabetes Care's net income of -$130.6M is lower than Abbott Laboratories's net income of $1.3B. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 17.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.39x versus 5.42x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.39x -- $234.4M -$130.6M ABTAbbott Laboratories5.42x 17.03x $10.4B $1.3B
-
Which has Higher Returns TNDM or ATEC?
Alphatec Holdings has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of -30.68%. Tandem Diabetes Care's return on equity of -81.14% beat Alphatec Holdings's return on equity of -691.37%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M ATECAlphatec Holdings68.56% -$0.35 $462.5M -
What do Analysts Say About TNDM or ATEC?
Tandem Diabetes Care has a consensus price target of $35.25, signalling upside risk potential of 70.13%. On the other hand Alphatec Holdings has an analysts' consensus of $18.32 which suggests that it could grow by 47.13%. Given that Tandem Diabetes Care has higher upside potential than Alphatec Holdings, analysts believe Tandem Diabetes Care is more attractive than Alphatec Holdings.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care7 10 0 ATECAlphatec Holdings5 1 0 -
Is TNDM or ATEC More Risky?
Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.249%.
-
Which is a Better Dividend Stock TNDM or ATEC?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or ATEC?
Tandem Diabetes Care quarterly revenues are $234.4M, which are larger than Alphatec Holdings quarterly revenues of $169.2M. Tandem Diabetes Care's net income of -$130.6M is lower than Alphatec Holdings's net income of -$51.9M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.39x versus 2.80x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.39x -- $234.4M -$130.6M ATECAlphatec Holdings2.80x -- $169.2M -$51.9M
-
Which has Higher Returns TNDM or BSX?
Boston Scientific has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 14.45%. Tandem Diabetes Care's return on equity of -81.14% beat Boston Scientific's return on equity of 9.57%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M BSXBoston Scientific68.84% $0.45 $33.6B -
What do Analysts Say About TNDM or BSX?
Tandem Diabetes Care has a consensus price target of $35.25, signalling upside risk potential of 70.13%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 11.93%. Given that Tandem Diabetes Care has higher upside potential than Boston Scientific, analysts believe Tandem Diabetes Care is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care7 10 0 BSXBoston Scientific23 3 0 -
Is TNDM or BSX More Risky?
Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.
-
Which is a Better Dividend Stock TNDM or BSX?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or BSX?
Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Tandem Diabetes Care's net income of -$130.6M is lower than Boston Scientific's net income of $674M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 76.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.39x versus 8.86x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.39x -- $234.4M -$130.6M BSXBoston Scientific8.86x 76.28x $4.7B $674M
-
Which has Higher Returns TNDM or ISRG?
Intuitive Surgical has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 30.99%. Tandem Diabetes Care's return on equity of -81.14% beat Intuitive Surgical's return on equity of 15.82%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M ISRGIntuitive Surgical64.69% $1.92 $17.2B -
What do Analysts Say About TNDM or ISRG?
Tandem Diabetes Care has a consensus price target of $35.25, signalling upside risk potential of 70.13%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 6.72%. Given that Tandem Diabetes Care has higher upside potential than Intuitive Surgical, analysts believe Tandem Diabetes Care is more attractive than Intuitive Surgical.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care7 10 0 ISRGIntuitive Surgical14 10 1 -
Is TNDM or ISRG More Risky?
Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.
-
Which is a Better Dividend Stock TNDM or ISRG?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or ISRG?
Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Tandem Diabetes Care's net income of -$130.6M is lower than Intuitive Surgical's net income of $698.4M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 79.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.39x versus 22.47x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.39x -- $234.4M -$130.6M ISRGIntuitive Surgical22.47x 79.11x $2.3B $698.4M
-
Which has Higher Returns TNDM or PODD?
Insulet has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 6.22%. Tandem Diabetes Care's return on equity of -81.14% beat Insulet's return on equity of 36.9%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M PODDInsulet71.88% $0.50 $3B -
What do Analysts Say About TNDM or PODD?
Tandem Diabetes Care has a consensus price target of $35.25, signalling upside risk potential of 70.13%. On the other hand Insulet has an analysts' consensus of $328.73 which suggests that it could grow by 2.29%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care7 10 0 PODDInsulet14 2 0 -
Is TNDM or PODD More Risky?
Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.
-
Which is a Better Dividend Stock TNDM or PODD?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or PODD?
Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Insulet quarterly revenues of $569M. Tandem Diabetes Care's net income of -$130.6M is lower than Insulet's net income of $35.4M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Insulet's PE ratio is 57.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.39x versus 10.81x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.39x -- $234.4M -$130.6M PODDInsulet10.81x 57.80x $569M $35.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus has flown under the radar, but the numbers tell…
Celsius Stock Forecast: Will Earnings Spark Another Surge?
Energy drink seller Celsius Holdings, Inc. (NASDAQ:CELH) has reported somewhat…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
